Metastatic pancreatic cancer is one of the most aggressive and highly lethal malignancies,
with an estimated 5-year survival of less than 5%. In 2013, approximately 45,000 new cases …

Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world.
Surgery remains the only treatment offering an advantage in terms of overall survival (5-year …

Purpose To provide evidence-based recommendations to oncologists and others for the
treatment of patients with metastatic pancreatic cancer. Methods American Society of …

Although pancreatic adenocarcinoma is the fourth leading cause of cancer death, only
modest improvement has been observed in the past two decades, single agent gemcitabine …

Purpose The relative value of gemcitabine-based combination chemotherapy therapy and
prolonged infusions of gemcitabine in patients with advanced pancreatic cancer remains …

In the past 15 years, we have seen few therapeutic advances for patients with pancreatic
cancer, which is the fourth leading cause of cancer-related death in the United States …

Adenocarcinoma of the pancreas or pancreatic cancer as we will refer to it here, is a cancer
of poor prognosis with a high mortality, particularly in the advanced or metastatic setting …

Background Data are lacking on the efficacy and safety of a combination chemotherapy
regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as …

Gemcitabine and nab-paclitaxel (GEM-NAB) and the combination of 5-fluorouracil,
oxaliplatin, and irinotecan (FOLFIRINOX) are valid first-line options for advanced or …

The current management of patients with metastatic pancreatic ductal adenocarcinoma
(mPDAC) is based on systemic chemotherapy. The results of the MPACT and PRODIGE …